Overall Technical outlook

Price Summary

Concord Biotech Limited's stock opened at 1675.0 on 2025-09-03, surged to a high of 1710.0, hit a low of 1649.0, and closed up 1.43% at 1698.9, with 155883 shares traded.
The stock reached its highest price of 2601.1 and lowest price of 1386.7 over the last 52 weeks.
The projected price range for Concord Biotech Limited is between 1600.0 and 1965.0, with an expected mean price of 1840.0, according to 5 analysts.

Technicals

Support and Resistance: At 1698.9, the price is supported at 1604.1 and faces resistance at 1747.45. This range suggests that the price for CONCORDBIO might stay between these levels, with 1604.1 acting as a floor and 1747.45 as a ceiling.
CONCORDBIO supportResistance 25c4cb
Support/Resistance for CONCORDBIO


Aroon: The AROON is in a neutral stance for CONCORDBIO, not indicating a clear upward or downward trend. This suggests a period of market indecision, where neither bulls nor bears have the upper hand.
CONCORDBIO aroon 25c4cb
Aroon chart for Concord Biotech Limited


Bol. Bands: The BOLL BANDS is showing a neutral stance, with no definitive indication of an upward or downward trend for CONCORDBIO. This neutral position suggests a period of indecision in the market, making it difficult to predict the next move.
CONCORDBIO bbands 25c4cb
Bolinger Bands chart for Concord Biotech Limited


Parabolic SAR: The PSAR has just shifted from bullish to bearish, hinting at a potential market decline. If this reversal is supported by other trends, it could be a very bearish signal for CONCORDBIO. Investors should be vigilant and seek further confirmation before taking action.
CONCORDBIO psar 25c4cb
Parabolic Stop and Reverse chart for Concord Biotech Limited


Stochastic: The STOCHASTIC is showing a neutral reading, with no clear direction indicated for upward or downward movement. This neutral position suggests a possible period of consolidation.
CONCORDBIO stoch 25c4cb
Stochastic chart for Concord Biotech Limited


Tripple Moving Agerage: The Tripple MOVING AVG is in a neutral stance, with no clear direction indicated for the market. This lack of clarity suggests that the market may be in a state of equilibrium for CONCORDBIO, with no strong trend emerging.
CONCORDBIO trippleSMA 25c4cb
Tripple SMA chart for Concord Biotech Limited


When evaluating a company, it is crucial to examine its fundamentals, including its financial statements, management structure, and market position. Additionally, understanding the broader industry trends, competition, and regulatory landscape helps to create a well-rounded view. By assessing both the company's internal factors and the external environment in which it operates, you can extract more valuable insights from its technical performance, such as stock price movements and trading patterns.